A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.
This is because even though antibody-mediated immunity wanes over time, specific memory B cells are induced after the first dose that increases significantly after the second. These cells increase over time, even two months from the second dose, indicating that the vaccine induces strong and sustained protection.
